Clinical trials: Concentration
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
CO-OP, Attention Control
CO-OPerative Training for Stroke Rehabilitation
Cognitive impairments occur frequently after stroke, and are associated with significant long-term activities of daily living (ADL) disability and poor quality of life.
- Trial name
- CO-OP (NCT02755805)
- Testing
- CO-OP, Attention Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Healthy
A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions
This study will compare the relative bioavailability of hydrocodone, acetaminophen, and promethazine in CL-108 (hydrocodone 7.5mg/ acetaminophen 325 mg/ promethazine 12.5 mg) manufactured by Charleston Laboratories, Inc.
- Trial name
- NCT02465866
- Testing
- CL-108, Vicoprofen, Ultracet
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Charleston Laboratories, Inc
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease.
- Trial name
- GalaNic (NCT02420327)
- Testing
- Nicotine patch and galantamine capsule
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Attention Deficit Hyperactivity Disorder, Adherence, Medication
Web Based Tools to Improve Medication Continuity in Adolescents With ADHD
Medication is an efficacious treatment strategy for adolescents with attention-deficit/hyperactivity disorder (ADHD), however use significantly declines during adolescence when the consequences of ADHD are most severe (e.g.
- Trial name
- NCT04386096
- Testing
- Mehealth for ADHD software with medication continuity tools, Mehealth for ADHD software with no medication continuity tools
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Brain Injury
Neural Bases of Cognitive Rehabilitation for Brain Injury
Some of the most common and disabling consequences of brain injury are deficits in cognition, such as difficulty with sustained attention, memory, organization, and goal management.
- Trial name
- NCT01120756
- Testing
- Goal-oriented attentional self-regulation, Brain Health Education
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
HIV
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV positive pregnant women who receive potent combination antiretroviral therapy over at least the last trimester of pregnancy, and who have proper obstetric interventions and are able to avoid breast feeding, decrease the risk…
- Trial name
- NCT01625169
- Testing
- Etravirine pharmacokinetics in breast milk and plasma
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
ADHD, Substance Use Disorders
Integrated Treatment for Adolescents With ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) exists in 20-50% of the 3 million adolescents annually enrolled in outpatient mental health and substance use treatment.
- Trial name
- CASALEAP IT2A (NCT02420990)
- Testing
- Medication Integration Protocol (MIP), Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- The National Center on Addiction and Substance Abuse at Columbia University
Schizophrenia, Schizoaffective Disorder
Improving Visual Attention in Schizophrenia
This study investigates whether visual attention can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).
- Trial name
- NCT03880227
- Testing
- Active anodal tDCS
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- The University of Texas at Dallas
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Heart Failure
Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.
Cognitive impairment (CI) is a prevalent problem in persons with HF heart failure (HF) and is associated with adverse clinical outcomes, higher mortality and poorer quality of life.
- Trial name
- EXCITE (NCT02151266)
- Testing
- Exercise and Cognitive retraining, Exercise Only, Stretching and Flexibility
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Emory University
Alzheimer's Disease
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo…
- Trial name
- NCT00930059
- Testing
- PF-04447943
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.
Cocaine Dependence
A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) and topiramate in the treatment of cocaine dependence.
- Trial name
- TACT (NCT00421603)
- Testing
- Adderall-XR and Topiramate
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- New York State Psychiatric Institute
Intrahepatic Cholestasis of Pregnancy
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Part 1 is an open-label randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability of two doses of volixibat.
- Trial name
- OHANA (NCT04718961)
- Testing
- Volixibat
- Where
- 20 sites in United States, New Zealand and 1 more
- Volunteers
- 4 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
- Trial name
- NCT03327402
- Testing
- SHP465
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire